Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a combination of prednisolone and cytosine arabinoside

The records of 11 dogs with evidence of meningoencephalomyelitis of unknown origin were reviewed. Two of them had had a focal form of the disease and the other nine a disseminated form. The forebrain was involved in five of the nine dogs with disseminated disease, the brainstem in all nine and the c...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary record 2008-02, Vol.162 (8), p.241-245
Main Authors: Menaut, P., Landart, J., Behr, S., Lanore, D., Trumel, C.
Format: Article
Language:English
Subjects:
Animals
Anti-Inflammatory Agents - therapeutic use
Blood
Cytarabine - adverse effects
Cytarabine - therapeutic use
cytosine
Disease
Dog Diseases - drug therapy
Dog Diseases - etiology
Dog Diseases - mortality
Dogs
Drug dosages
Drug Therapy, Combination
Female
Immunosuppressive Agents - therapeutic use
Male
Medical prognosis
meningoencephalitis
Meningoencephalitis - drug therapy
Meningoencephalitis - etiology
Meningoencephalitis - mortality
Meningoencephalitis - veterinary
prednisolone
Prednisolone - therapeutic use
Retrospective Studies
Steroids
Studies
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The records of 11 dogs with evidence of meningoencephalomyelitis of unknown origin were reviewed. Two of them had had a focal form of the disease and the other nine a disseminated form. The forebrain was involved in five of the nine dogs with disseminated disease, the brainstem in all nine and the cerebellum in one. They had been treated with courses of cytosine arabinoside every three weeks and immunosuppressive doses of prednisolone. Their response to the treatment, in terms of quality of life, was judged by their owners and referring veterinarians to have been excellent in five, good in five and poor in one; their survival times ranged from 78 days to more than 603 days. The cumulative probability of survival at two years was 58·4 per cent. No signs of myelosuppression or other side effects associated with cytosine arabinoside were observed.
ISSN:0042-4900
2042-7670
DOI:10.1136/vr.162.8.241